JPRN-UMIN000008024
Completed
Phase 2
Phase II clinical trial of combination chemotherapy with bendamustine and rituximab for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patients - Bendamustine and rituximab salvage trial for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patients
Kyoto University Hematology Study Group0 sites45 target enrollmentJune 4, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Sponsor
- Kyoto University Hematology Study Group
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1, pregnant or breast\-feeding women 2, patients with active second cancer 3, HBs antigen positive or HBV\-DNA positive patients 4, HIV antibody positive patients 5, patients who have been treated with stem cell transplantation 6, interstitial pneumonitis or pulmonary fibrosis 7, patients with central nervous system involvement 8, patients who have already received bendamustine treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II trial of combination chemotherapy consisting of S-1 and Oxaliplatin in patients with advanced or recurrent mucinous adenocarcinoma of the ovaryMucinous adenocarcinoma of the ovary including metastatic ovarian cancerJPRN-UMIN000001541Japan ovarian mucinous adenocarcinoma study group40
Completed
Not Applicable
Phase II trial of combination chemotherapy consisting of pegylated liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancerEpithelial ovarian cancer, primary fallopian tube cancer, or peritoneal cancer in late relapse (>6 months) after 1st-line chemotherapyJPRN-UMIN000002691Keio University, School of Medicine33
Completed
Phase 2
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
Active, not recruiting
Not Applicable
Klinisk prövning med kombinationsbehandling av kemoterapi och antikroppar för behandling av patienter med gallgångscancer som inte kan opereras.EUCTR2010-020385-13-SEVejle Hospital78
Active, not recruiting
Phase 1
Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations - GOC-B-PEUCTR2010-020385-13-DKVejle Hospital